- / Nov 26, 2024 / Business Wire / UnitedHealth Group (NYSE: UNH) will host its annual Investor Conference for analysts and institutional investors in New York City on Wednesday, December 4, 2024, beginning at 8:00 a.m. EST.
UnitedHealth Group leaders will discuss the company’s long-term strategic growth priorities and its efforts to advance high-quality health care, including through a continued focus on improving the consumer experience and expanding value-based care. Management will also provide its outlook for growth and performance in 2025.
The company will stream the presentations and management question and answer sessions and will make conference materials available on its Investor Relations page at www.unitedhealthgroup.com. A replay of the conference will be available on the Company website.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.
Last Trade: | US$305.71 |
Daily Change: | 2.00 0.66 |
Daily Volume: | 3,781,274 |
Market Cap: | US$277.320B |
May 13, 2025 January 16, 2025 October 15, 2024 July 16, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load